Central Pharmaceutical Joint Stock Company No3 (HNX:DP3)
63,400
+100 (0.16%)
At close: Feb 9, 2026
HNX:DP3 Balance Sheet
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 4,476 | 13,706 | 5,375 | 21,106 | 24,727 |
Short-Term Investments | 471,053 | 327,987 | 301,000 | 185,378 | 137,000 |
Cash & Short-Term Investments | 475,528 | 341,693 | 306,375 | 206,484 | 161,727 |
Cash Growth | 39.17% | 11.53% | 48.38% | 27.67% | 0.50% |
Accounts Receivable | 43,409 | 34,817 | 17,061 | 26,898 | 20,857 |
Other Receivables | 7,316 | 4,539 | 5,722 | 1,758 | 318.51 |
Receivables | 50,725 | 39,356 | 22,784 | 28,656 | 21,175 |
Inventory | 56,696 | 43,925 | 52,332 | 69,835 | 67,159 |
Prepaid Expenses | 306.77 | 222.42 | 247.03 | 49.57 | 334.52 |
Other Current Assets | 4,396 | 8,129 | 2,014 | 5,161 | 5,050 |
Total Current Assets | 587,651 | 433,326 | 383,752 | 310,186 | 255,446 |
Property, Plant & Equipment | 114,288 | 119,745 | 131,247 | 154,414 | 145,838 |
Other Intangible Assets | 20,121 | 20,201 | 20,281 | 6,514 | 6,594 |
Other Long-Term Assets | 34,128 | 34,504 | 35,346 | 36,755 | 37,626 |
Total Assets | 756,189 | 607,777 | 570,626 | 507,868 | 445,504 |
Accounts Payable | 20,212 | 7,642 | 15,695 | 18,474 | 19,499 |
Accrued Expenses | 63,142 | 63,340 | 59,112 | 50,742 | 44,398 |
Short-Term Debt | 34,273 | - | 6,800 | 5,230 | 3,528 |
Current Income Taxes Payable | 21,358 | 13,243 | 14,240 | 10,594 | 8,084 |
Current Unearned Revenue | 3,082 | - | - | - | - |
Other Current Liabilities | 6,180 | 4,671 | 5,333 | 5,378 | 3,746 |
Total Current Liabilities | 148,247 | 88,896 | 101,179 | 90,418 | 79,254 |
Long-Term Debt | - | - | 975 | - | - |
Total Liabilities | 148,247 | 88,896 | 102,154 | 90,418 | 79,254 |
Common Stock | 214,999 | 214,999 | 214,999 | 86,000 | 86,000 |
Additional Paid-In Capital | - | - | - | 97,659 | 97,659 |
Retained Earnings | 392,943 | 303,881 | 253,473 | 233,791 | 182,591 |
Shareholders' Equity | 607,942 | 518,881 | 468,472 | 417,450 | 366,250 |
Total Liabilities & Equity | 756,189 | 607,777 | 570,626 | 507,868 | 445,504 |
Total Debt | 34,273 | - | 7,775 | 5,230 | 3,528 |
Net Cash (Debt) | 441,256 | 341,693 | 298,600 | 201,254 | 158,199 |
Net Cash Growth | 29.14% | 14.43% | 48.37% | 27.21% | 1.71% |
Net Cash Per Share | 20523.58 | 15892.74 | 13888.41 | 8892.41 | 7358.34 |
Filing Date Shares Outstanding | 21.5 | 21.5 | 21.5 | 21.5 | 21.5 |
Total Common Shares Outstanding | 21.5 | 21.5 | 21.5 | 21.5 | 21.5 |
Working Capital | 439,405 | 344,430 | 282,572 | 219,768 | 176,192 |
Book Value Per Share | 28276.47 | 24134.06 | 21789.47 | 19416.28 | 17034.87 |
Tangible Book Value | 587,821 | 498,679 | 448,191 | 410,936 | 359,656 |
Tangible Book Value Per Share | 27340.59 | 23194.45 | 20846.14 | 19113.30 | 16728.17 |
Buildings | 128,321 | 126,884 | 126,668 | - | - |
Machinery | 109,865 | 109,367 | 109,269 | - | - |
Construction In Progress | 3,864 | 120 | 401.11 | 14,390 | 5,436 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.